TY  - JOUR
AU  - Conteduca, Vincenza
AU  - Jayaram, Anuradha
AU  - Romero-Laorden, Nuria
AU  - Wetterskog, Daniel
AU  - Salvi, Samanta
AU  - Gurioli, Giorgia
AU  - Scarpi, Emanuela
AU  - Castro, Elena
AU  - Marin-Aguilera, Mercedes
AU  - Lolli, Cristian
AU  - Schepisi, Giuseppe
AU  - Maugeri, Antonio
AU  - Wingate, Anna
AU  - Farolfi, Alberto
AU  - Casadio, Valentina
AU  - Medina, Ana
AU  - Puente, Javier
AU  - Vidal, Mª José Méndez
AU  - Morales-Barrera, Rafael
AU  - Villa-Guzmán, Jose C
AU  - Hernando, Susana
AU  - Rodriguez-Vida, Alejo
AU  - González-Del-Alba, Aránzazu
AU  - Mellado, Begoña
AU  - Gonzalez-Billalabeitia, Enrique
AU  - Olmos, David
AU  - Attard, Gerhardt
AU  - De Giorgi, Ugo
PY  - 2018
DO  - 10.1016/j.eururo.2018.09.049
UR  - http://hdl.handle.net/10668/13576
T2  - European urology
AB  - Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. We aimed to evaluate...
LA  - en
KW  - Androgen receptor
KW  - Androgen receptor–directed therapies
KW  - Biomarker
KW  - Castration-resistant prostate cancer
KW  - Docetaxel
KW  - Plasma DNA
KW  - Androgen Antagonists
KW  - Androstenes
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Benzamides
KW  - Docetaxel
KW  - Humans
KW  - Kallikreins
KW  - Male
KW  - Neoplasm Metastasis
KW  - Nitriles
KW  - Phenylthiohydantoin
KW  - Progression-Free Survival
KW  - Prostate-Specific Antigen
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Receptors, Androgen
KW  - Spain
KW  - Time Factors
TI  - Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
TY  - research article
VL  - 75
ER  -